Lorglumide

Lorglumide
Clinical data
Other names	4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
ATC code	none;
Identifiers
	IUPAC name N2-(3,4-Dichlorobenzoyl-N,N-dipentyl-α-glutamine;
CAS Number	97964-56-2 ;
PubChem CID	3960;
IUPHAR/BPS	891;
ChemSpider	3823 ;
UNII	LAD1UQ73BE;
ChEBI	CHEBI:88305 ;
ChEMBL	ChEMBL24938 ;
CompTox Dashboard (EPA)	DTXSID2046961 ;
Chemical and physical data
Formula	C22H32Cl2N2O4
Molar mass	459.41 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl;
	InChI InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28) ; Key:IEKOTSCYBBDIJC-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lorglumide (CR-1409) is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a cholecystokinin antagonist,^[1] with fairly high selectivity for the CCK_A subtype.^[2] It has been suggested as a potential treatment for a variety of gastrointestinal problems including stomach ulcers, irritable bowel syndrome, dyspepsia, constipation and pancreatitis, as well as some forms of cancer, but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research.^[3]^[4]^[5]^[6]